StreetInsider.com top ticker, 09/22/2022
News and research before you hear about it on CNBC and others. Claim your 1 week free trial StreetInsider Premium here.
CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) — Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treating cardiovascular disease with one-course gene-editing drugs , announced today that management will be attending the following upcoming investor conferences:
- Guggenheim 2022 Nantucket Therapeutics Conference (fireside chat) on Wednesday, September 28, 2022 at 7:30 p.m. ET in Nantucket, Mass.;
- Jefferies Cell and Genetic Medicine Summit 2022 (fireside chat) on Thursday, September 29, 2022 at 3:00 p.m. ET in NYC;
- Chardan 6th Annual Genetic Medicine Conference (fireside chat) on Tuesday, October 4, 2022 at 8:00 a.m. ET in NYC;
- BMO Virtual Biopharma Spotlight Series: Gene Editing & Therapeutics (fireside chat) on Thursday, October 6, 2022 at 9:50 am ET; and,
- 2022 Truist Securities Genetic Medicine Summit Rare/Non-Rare Disease Panel (panel) on Thursday, October 20, 2022 at 1:15 p.m. ET.
Live webcasts are available on the Investors section of the Company’s website at www.vervetx.com and will be archived for 60 days after the presentations.
About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage genetic medicines company developing a new approach to treating cardiovascular disease, potentially moving treatment from chronic disease management to gene-editing drugs in one changed course. The Company’s first two programs, VERVE-101 and VERVE-201, target genes that have been extensively validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease were used to permanently lower the LDL -C level in the blood. VERVE-101 is designed to turn that off permanently PCSK9 Gene in the liver and is being developed initially for heterozygous familial hypercholesterolaemia (HeFH) and eventually for the treatment of atherosclerotic cardiovascular disease (ASCVD), which is not effective with oral therapy. VERVE-201 is designed to turn that off permanently ANGPTL3 gene in the liver and is being developed first in homozygous familial hypercholesterolemia (HoFH) and eventually in patients with ASCVD who have failed to achieve target LDL-C with oral therapy and a PCSK9 inhibitor. Visit www.VerveTx.com for more information.
investor contactJen Robinson Verve Therapeutics, Inc.[email protected]
media contactAshlea Kosikowski1AB[email protected]
Source: Verve Therapeutics
Serious news for serious traders! Try StreetInsider.com Premium for free!